Share Prices & Company Research

Market News

26 Jan 2021 | 08:42

Hikma mulls acquisition of GlaxoSmithKline assets in Egypt and Tunisia

(Sharecast News) - Drugmaker Hikma Pharmaceuticals said on Tuesday that it has entered into a non-binding term sheet with GlaxoSmithKline to acquire certain parts of latter's assets in Egypt and Tunisia. Hikma will potentially acquire GSK's interests in certain entities that conduct, and certain assets comprising, Glaxo's pharmaceutical and consumer commercialisation and manufacturing business in Egypt and its pharmaceutical business in Tunisia.

Subject to receipt of consent from the board of GlaxoSmithKline, Hikma will conduct a due diligence exercise, the results of which will form the basis for further discussions with GSK.

The FTSE 250-listed firm highlighted that the proposed transaction was subject to a number of conditions, including the finalisation of definitive and legally binding documents and the completion of due diligence.

"As such, there can be no guarantee at this stage that the proposed transaction will progress," concluded Hikma.

As of 0840 GMT, Hikma shares were down 0.08% at 2,492.0p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.